title: Eculizumab for the treatment of atypical hemolytic uremic syndrome recurrence after kidney transplantation associated with complement factor H mutations: a case report with a 5-year follow-up.
authors: Department of Urology, Kidney Center, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku, Tokyo, 162-8666, Japan. okumi@kc.twmu.ac.jp.
authors: Masayoshi
authors: M
authors: Okumi
authors: Department of Urology, Kidney Center, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku, Tokyo, 162-8666, Japan.
authors: Kazuya
authors: K
authors: Omoto
authors: Department of Internal Medicine, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan.
authors: Kohei
authors: K
authors: Unagami
authors: Department of Urology, Kidney Center, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku, Tokyo, 162-8666, Japan.
authors: Hideki
authors: H
authors: Ishida
authors: Department of Urology, Kidney Center, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku, Tokyo, 162-8666, Japan.
authors: Kazunari
authors: K
authors: Tanabe
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D065766:Atypical Hemolytic Uremic Syndrome / Q000188:drug therapy* / Q000235:genetics*; D017242:Complement Factor H / Q000235:genetics*; D005500:Follow-Up Studies; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D012008:Recurrence; D013997:Time Factors; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D017242:Complement Factor H; C481642:eculizumab